Selective substrates for matrix metalloproteinases
View Patent ↗The invention provides isolated MMP-2, MMP-9 and MT1-MMP selective substrate polypeptides or functional peptidomimetics. The selective substrate polypeptides contain the following sequences: MMP-2 selective substrate polypeptides contain SEQ ID NOS:1-27, MMP-9 selective substrate polypeptides contain SEQ ID NOS:28-35, and MT1-MMP selective substrate polypeptide contain SEQ ID NOS:36-40. In addition, the invention provides a method of preferentially directing a moiety to a site of MMP-2 activity by administering to a subject an effective amount of an isolated MMP-2 selective substrate polypeptide containing SEQ ID NOS:45-47 linked to a moiety. Also provided is a method of preferentially directing a moiety to a site of MMP-9 activity by administering to a subject an effective amount of an isolated MMP-9 selective substrate polypeptide containing SEQ ID NO:44 linked to a moiety, and preferentially directing a moiety to a site of MT1-MMP activity by administering to a subject an effective amount of an isolated MT1-MMP selective substrate polypeptide containing SEQ ID NOS:36-40 linked to a moiety.
1. An isolated matrix metalloproteinase-2 (MMP-2)selective substrate polypeptide, comprising the amino acid sequence selected from the group consisting of: SEQ ID NOS:10 and 11, wherein said MMP-2 selective substrate polypeptide has 100 or fewer amino acids and can be hydrolyzed by MMP-2.
2. The isolated MMP-2 selective substrate polypeptide of claim 1 , wherein said polypeptide is linked to a moiety.
3. The isolated MMP-2 selective substrate polypeptide of claim 2 , wherein said moiety is a diagnostic agent.
4. The isolated MMP-2 selective substrate polypeptide of claim 3 , wherein said diagnostic agent is a quenched fluorophore.
5. The isolated MMP-2 selective substrate polypeptide of claim 2 , wherein said moiety is a therapeutic moiety.
6. The isolated MMP-2 selective substrate polypeptide of claim 5 , wherein said therapeutic moiety is a chemotherapeutic agent.
7. The isolated MMP-2 selective substrate polypeptide of claim 5 , wherein said therapeutic moiety is selected from the group consisting of an anti-angiogenic agent, a pro-angiogenic agent and an agent that promotes tissue repair.
8. The isolated MMP-2 selective substrate polypeptide of claim 1 , wherein said amino acid sequence is SEQ ID NO:10.
9. The isolated MMP-2 selective substrate polypeptide of claim 1 , wherein said amino acid sequence is SEQ ID NO:11.
10. The isolated MMP-2 selective substrate of claim 1 , wherein said MMP-2 selective substrate polypeptide has 40 or fewer amino acids.
11. The isolated MMP-2 selective substrate of claim 1 , wherein said MMP-2 selective substrate polypeptide has 20 or fewer amino acids.
12. The isolated MMP-2 selective substrate of claim 1 , wherein said MMP-2 selective substrate polypeptide has 10 or fewer amino acids.
13. An isolated matrix metalloproteinase-2 (MMP-2) selective substrate polypeptide, consisting of the amino acid sequence selected from the group consisting of: SEQ ID NOS:10 and 11, wherein said MMP-2 selective substrate polypeptide can be hydrolyzed by MMP-2.
14. The isolated MMP-2 selective substrate polypeptide of claim 13 , wherein said amino acid sequence is SEQ ID NO:10.
15. The isolated MMP-2 selective substrate polypeptide of claim 13 , wherein said amino acid sequence is SEQ ID NO:11.
16. The isolated MMP-2 selective substrate polypeptide of claim 13 , wherein said polypeptide is linked to a moiety.
17. The isolated MMP-2 selective substrate polypeptide of claim 16 , wherein said moiety is a diagnostic agent.
18. The isolated MMP-2 selective substrate polypeptide of claim 17 , wherein said diagnostic agent is a quenched fluorophore.
19. The isolated MMP-2 selective substrate polypeptide of claim 16 , wherein said moiety is a therapeutic moiety.
20. The isolated MMP-2 selective substrate polypeptide of claim 19 , wherein said therapeutic moiety is a chemotherapeutic agent.
21. The isolated MMP-2 selective substrate polypeptide of claim 19 , wherein said therapeutic moiety is selected from the group consisting of an anti-angiogenic agent, a pro-angiogenic agent and an agent that promotes tissue repair.
22. A fusion protein comprising a polypeptide fused to a matrix metalloproteinase-2 (MMP-2) selective substrate polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOS:10 and 11, wherein said MMP-2 selective substrate polypeptide can be hydrolyzed by MMP-2.
23. The fusion protein of claim 22 , wherein said amino acid sequence is SEQ ID NO:10.
24. The fusion protein of claim 22 , wherein said amino acid sequence is SEQ ID NO:11.